Trial Information
High Plasma Level of Long Pentraxin 3 is Associated With Insulin Resistance in Women With Polycystic Ovary Syndrome
Inclusion Criteria:
- Absence of significant abnormalities on physical examination except hirsutism
- No lipid lowering, hypoglycemic, antihypertensive or hormone replacement therapy
- Normal thyroid function and prolactin level
- Absence of history or evidence of metabolic, cardiovascular, respiratory or hepatic
disease
Exclusion Criteria:
- Pregnant
- Possible ovarian tumors,
- Congenital adrenal hyperplasia or
- BMI greater than 35 kg/m2
Type of Study:
Observational
Study Design:
Observational Model: Case Control, Time Perspective: Cross-Sectional
Outcome Measure:
Level of of pentraxin3 in cases with Polycystic Ovarian Syndrome
Outcome Description:
Mean PTX3 was significantly higher in patients with PCOS. This means that there is increased level of inflamation in patients with PCOS.
Outcome Time Frame:
1 year
Safety Issue:
Yes
Principal Investigator
Aydogan Aydogdu, MD
Investigator Role:
Principal Investigator
Investigator Affiliation:
Gulhane School of Medicine Dep. of Endocrinology and Metabolism
Authority:
Turkey: Ethics Committee
Study ID:
23.10.2011
NCT ID:
NCT01463969
Start Date:
May 2010
Completion Date:
May 2011
Related Keywords:
- PCOS
- PCOS and PTX3 levels
- Insulin Resistance
- Polycystic Ovary Syndrome